The Producers Life Insurance coverage Firm bought a brand new place in OmniAb, Inc. (NASDAQ:OABI – Free Report) through the second quarter, HoldingsChannel.com stories. The fund bought 39,103 shares of the corporate’s inventory, valued at roughly $147,000.
A number of different hedge funds and different institutional buyers have additionally modified their holdings of OABI. Hartline Funding Corp acquired a brand new stake in OmniAb through the first quarter price about $54,000. Bellevue Group AG acquired a brand new stake in shares of OmniAb through the 1st quarter price roughly $62,000. Catalina Capital Group LLC purchased a brand new stake in shares of OmniAb within the 1st quarter price roughly $69,000. Value T Rowe Associates Inc. MD boosted its place in OmniAb by 13.1% through the 1st quarter. Value T Rowe Associates Inc. MD now owns 26,843 shares of the corporate’s inventory valued at $146,000 after buying a further 3,108 shares through the interval. Lastly, Sei Investments Co. grew its stake in OmniAb by 11.0% through the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the corporate’s inventory price $109,000 after shopping for a further 2,888 shares over the past quarter. 72.08% of the inventory is owned by institutional buyers and hedge funds.
OmniAb Inventory Up 0.2 %
Shares of NASDAQ:OABI opened at $4.08 on Friday. The corporate’s fifty day shifting common is $4.19 and its two-hundred day shifting common is $4.37. The corporate has a market cap of $479.87 million, a P/E ratio of -6.38 and a beta of -0.13. OmniAb, Inc. has a 12-month low of $3.56 and a 12-month excessive of $6.72.
OmniAb (NASDAQ:OABI – Get Free Report) final issued its earnings outcomes on Thursday, August eighth. The corporate reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. OmniAb had a damaging web margin of 287.29% and a damaging return on fairness of 20.21%. The corporate had income of $7.61 million through the quarter, in comparison with analyst estimates of $6.52 million. Throughout the identical quarter final 12 months, the enterprise posted ($0.15) EPS. Equities analysis analysts anticipate that OmniAb, Inc. will put up -0.58 earnings per share for the present 12 months.
Analysts Set New Value Targets
OABI has been the subject of quite a lot of current analysis stories. Benchmark reiterated a “purchase” ranking and issued a $8.00 goal value on shares of OmniAb in a analysis be aware on Monday, August nineteenth. HC Wainwright reiterated a “purchase” ranking and issued a $11.00 value goal on shares of OmniAb in a analysis report on Monday, August twelfth. Lastly, Royal Financial institution of Canada restated an “outperform” ranking and issued a $7.00 goal value on shares of OmniAb in a analysis report on Friday, August sixteenth.
Learn Our Newest Evaluation on OmniAb
OmniAb Profile
OmniAb, Inc, a biotechnology firm, engages within the discovery and provision of therapeutic antibody discovery applied sciences in america. The corporate’s know-how platform creates and screens numerous antibody repertoires and determine optimum antibodies for companions’ drug improvement efforts.
Really helpful Tales
Need to see what different hedge funds are holding OABI? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for OmniAb, Inc. (NASDAQ:OABI – Free Report).
Obtain Information & Scores for OmniAb Each day – Enter your e-mail tackle beneath to obtain a concise day by day abstract of the newest information and analysts’ rankings for OmniAb and associated corporations with MarketBeat.com’s FREE day by day e-mail e-newsletter.
